PharmaCyte Biotech's Total Assets for the quarter that ended in Jan. 2025 was $43.83 Mil.
During the past 12 months, PharmaCyte Biotech's average Total Assets Growth Rate was 166.80% per year.
During the past 3 years, the average Total Assets Growth Rate was 23.20% per year.
During the past 5 years, the average Total Assets Growth Rate was 9.10% per year.
During the past 10 years, the average Total Assets Growth Rate was 1.60% per year.
During the past 13 years, PharmaCyte Biotech's highest 3-Year average Total Assets Growth Rate was 258.90%. The lowest was -42.10%. And the median was 0.30%.
The historical data trend for PharmaCyte Biotech's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
PharmaCyte Biotech's Total Assets for the fiscal year that ended in Apr. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PharmaCyte Biotech (NAS:PMCB) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Jan. 2025) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
PharmaCyte Biotech's Asset Turnover for the quarter that ended in Jan. 2025 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
PharmaCyte Biotech Total Assets Related Terms
Thank you for viewing the detailed overview of PharmaCyte Biotech's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PMCB has been successfully added to your 